Despite a continued focus on traditional markers to manage cardiovascular risk, assessment has evolved beyond lipid values. Studies have shown that assessing low-density lipoprotein (LDL) particle number, size, and density can help identify residual risk among patients already being monitored or treated with statin therapy.
Download our white paper to:
Looking beyond traditional risk factors can help you improve your management of cardiovascular patients. Find out how in “Size and Density Matter: How Advanced Lipid Testing Can Uncover Residual Risk.”
Complete the form and click submit.
*Indicates required fields